New antibody aims to wipe out hidden cancer cells after transplant
NCT ID NCT07409454
First seen Feb 14, 2026 · Last updated May 13, 2026 · Updated 8 times
Summary
This study tests a drug called CM336 (a BCMA/CD3 bispecific antibody) as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. The goal is to turn minimal residual disease (MRD) from positive to negative, meaning no detectable cancer cells. About 20 adults will receive the drug, and researchers will monitor how long the effect lasts and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.